• Biomolecules & Therapeutics
• /
• 제5권3호
• /
• pp.299-305
• /
• 1997

In order to investigate the pharmacological properties of ι-muscone, effects of ι-muscone and musk were studied on the cardiovascular system with various experimental models. In isolated rat aorta, ι-muscone and musk made the relaxation of blood vessels in maximum contractile response to phenylephrine (10$^{-6}$ M) in endothelium-containing rings of the rat aorta, but not in endothelium-denuded rings. However, ι-muscone and musk in the presence of the inhibitor of NO synthase and guanylate cyclase did not make the relaxation of blood vessels. In spontaneously hypertensive rats (SHRs), ι-muscone and musk slightly reduced blood pressure but significantly decreased heart rate. In the isolated perfused rat hearts, ι-muscone and musk did not affect significantly on LVDP, contractile force, coronary flow and (-dp/dt)/(+dp/dt). These results suggest that ι-muscone and musk have weak cardiovascular effects with relaxation of blood vessel and decrease of heart rate, but without significant cardiac functions.

• Biomolecules & Therapeutics
• /
• 제5권3호
• /
• pp.306-315
• /
• 1997

In order to investigate pharmacological properties of ι -muscone, effects of ι-muscone and musk on cerebral ischemia and central nervous system were compared. Cerebral ischemia insult was performed using unilateral carotid artery occlusion in Mongolian gerbils. The histological observations showed a preventive effect of the ι-muscone treatment with ischemia-induced brain damage. The ATP in brain tissue was decreased in vehicle-treated ischemic gerbils. This decrease was prevented by the ι-muscone treatment. In contrast to what was seen with ATP, the lactate and lipid peroxide were both elevated in vehicle-treated ischemic gerbils.˙ This elevation was prevented by the ι-muscone treatment. While ι-muscone had no effects on the hexobarbital-induced sleeping time and the convulsions induced by electric shock, pentetrazol and strychnine, it had effect on rotarod test and spontaneous activity test. Respiration rate and depth were increased by the ι-muscone treatment. Furthermore, ι-muscone showed anti-stress effect. Our findings suggest that the pharmacological profile of ι-muscone on cerebral ischemia and central nervous system are similar to that of musk.

• Journal of Pharmaceutical Investigation
• /
• 제27권4호
• /
• pp.265-269
• /
• 1997

An inclusion complex of muscone with ${\beta}-cyclodextrin$ (CD), as a solid form of muscone, was prepared to increase the solubility of muscone. The molar ratio of muscone to ${\beta}-CD$ in complex was in the range of $1:1{\sim}1:5$ when prepared by freeze-drying method. The interaction of muscone with ${\beta}-CD$ in solid state was investigated by Infrared (IR) spectroscopy and differential scanning calorimetry (DSC). IR and DSC studies between $muscone-{\beta}-CD$ inclusion complex and physical mixture showed that $muscone-{\beta}-CD$ inclusion complex was prepared stably. From the amount of muscone incorporated in the inclusion complex, it was found that the molar ratio of muscone : ${\beta}-CD$ was 1:1. Relative spatial position of muscone and ${\beta}-CD$ was observed by Hyperchem molecular modelling program.

• Toxicological Research
• /
• 제13권4호
• /
• pp.435-447
• /
• 1997

l-Muscone is synthesized for use as substitutive material of musk which is the active ingredient of woohwangchungsimwon. The objective of this investigation was to evaluate the acute and subacute toxicity of l-muscone in rats. In oral acute toxicity test, SPF Sprague-Dawley male and female rats were gayaged with l-muscone of two doses(0, 5.0 g/kg). No dead animal and abnormal autopsy findings were found in control and treated group. Body weights were slightly decreased in both sexes of rats treated with 5.0 g/kg. Therefore, oral $LD_{50}$ of l-muscone was consider to be higher than 5.0 g/kg in male and female rats. In intraperitoneal acute toxicity test, rats were injected intraperitoneally with dosages of 0, 1,000, 1,316, 1,732, 2,279 and 3.000 mg/kg. Decreased body weights and motor activities were observed at high dose group. Intraperitoneal $LD_{50}$ of l-muscone were 1,920 mg/kg in male and female rats. In the subacute study, l-muscone was administrated orally to both sexes of rats for 4 weeks as several doses(0, 10, 100 and 1,000 mg/kg). There were neither dead animals nor significant changes of body weights during the experimental period. In addition, no differences were found between control and treated groups in clinical signs, urinalysis, hematology, serum biochemical analysist and other findings. Above data suggest that no observed adverse effect level of l-muscone in rats might be over 1,000 mg/kg/day in this study.

• Biomolecules & Therapeutics
• /
• 제5권3호
• /
• pp.292-298
• /
• 1997

General pharmacological properties of ι-muscone, the major component of musk, were investigatedin mice, rats and guinea pig. The administration of ι-muscone (1, 10, 100 mg/kg, p.o.) in mice had no effects in general behaviors, and no influences on analgesic actions and normal body temperature. Muscle relaxant action, intestinal propulsion and gastric secretion were not observed even at the high dose of 100 mg/kg. ι-Muscone (1, 10, 100 mg/kg, p.o.) given to conscious rats showed no effect on mean blood pressure and heart rate. It showed no direct effect at 2.4$\times$10.3 mg/ml and 2.4$\times$10-2 mg/ml in isolated uterus of rats and ileum of guinea pig, and also had no inhibition of contraction induced by oxytocin and histamine.

• Toxicological Research
• /
• 제13권4호
• /
• pp.449-460
• /
• 1997

Single and 4 weeks oral administration of l-muscone, a major active ingredient of musk, to beagle dogs of both sexes were performed to investigate both acute and subacute toxicity. Beagle dogs(3 males and 3 females) in acute experiments were administered orally with single dosage of 2,000 mg/kg and groups of 9 male and 9 female beagle dogs in subacute experiments were given daily different dosage of l-muscone, 0.2 mg/kg/day(low dosage group), 2 mg/kg/day(middle dosage group), or 20 mg/kg/day(high dosage group) once a day for 4 weeks by oral route according to the Established Regulation of Korean Food and Drug Administration(1996.4.16). $LD_{50}$ value for beagle dogs was more than 2,000 mg/kg on oral route for both male and females. In animals administered with l-muscone, there were neither dead animals nor significant changes of body weights. In addition, no differences were found between control and treated groups in clinical signs, urinalysis, eye examination, hematology, serum chemistry, organ weight and other findings. No histolopathological lesions were observed in both control and treatment groups. Above data strongly suggest that l-muscone in beagle dogs is considered to be safe.

• Archives of Pharmacal Research
• /
• 제27권5호
• /
• pp.539-543
• /
• 2004

An efficient analytical method was devised for the accurate L-muscone assay in aqueous samples. It involves solid-phase extraction of L-muscone in adsorption mode using XAD-4 as the sorbent and dichloromethane modified with 10% (v/v) methanol as the eluting solvent. The gas chromatographic analysis of the eluate residue dissolved in toluene on a DB-5MS capillary column provided complete resolution of L-muscone from the co-extracted interferences. The overall method showed excellent linearity ($r^2{\geq}$ 0.9994) in the range of 0.1 to 2.0 $\mu\textrm{g}$/mL with good intra- and inter-day precisions (% RSD = 2.5～7.3) and with high extraction recovery rates ($\geq$ 98.1 %). When the present method was applied to a L-muscone herbal drink product, the within-batch RE (%) in the labeled concentration (1.5 $\mu\textrm{g}$/mL) for the three randomly chosen bottles were -2.4, -1.3 and -3.3 with high precision (% RSD $\leq$ 3.1). The present method is considered to be suitable for quality control evaluation on liquid drinks and other complex formulations fortified with L-muscone.

• 대한화학회지
• /
• 제40권4호
• /
• pp.243-248
• /
• 1996

Cyclopentadecanone(2)으로부터 2-cyclopentadecen-1-one(4)까지의 일반적인 합성경로는 여러가지가 있을 수 있다. 본 실험에서는 우선 $C_2$-위치의 선택적인 브롬화반응을 위하여 $AlCl_3$를 써서 엔올산 염화하여 위치선택성을 증가시켰으며, 브롬화 수소 이탈반응에서의 시약 $Li_2CO_3$-LiBr-DMF 조건을 적절히 조절함으로써 화합물(4)를 쉽게 얻을 수 있었다. 이 과정에서 생기는 트랜스형 및 시스형 화합물(4)를 E.Ether 용매속에서 $CH_3MgI-Cu_2Cl_2$ 복합체에 적하하여 반응시킬 경우, 모두 1,4-첨가반응되어 dl-Muscone(1)를 생성함을 결과로 얻었다. 본 실험에서 Cyclopentadecanone(2)으로부터 dl-Muscone(1)까지의 3단계 과정을 통해 순수한 dl-Muscone(1)을 총 85%의 높은 수율로 얻었으며, 별다른 화학적 분리단계를 거치지 않아, 합성단가를 기존의 어느 방법보다 현격히 낮출수 있었다.

• 생약학회지
• /
• 제40권4호
• /
• pp.303-308
• /
• 2009

Essential oils of the musk from wild muskrat (Ondatra zibethicus) were analyzed by gas chromatography/mass spectrometry. Fifty-six chemical components were separated, and 14 volatile compounds (78% of composition of total essential oil) of macrocyclic musk, mainly cyclopentadecanone, 12-hydroxy-14-methyl-oxa-cyclotetradec-6-en-2-one, cycloheptadecanone and 9-cycloheptadecen-1-one, were identified by the comparison of Wiley/NBS Library from the results of GC-MS. However, l-muscone, a compound reported by earlier workers in the musk from muskrat, was not detected using the spike test in this study. Interestingly, cyclohexadecanone, which has the same molecular weight (Mw 238) as l-muscone, was identified. In addition, it is considered that because of possessing much higher amounts of macrocyclic components compared to the original musk, muskrat has higher economic values in perfume and pharmaceutical industries.

• Toxicological Research
• /
• 제14권2호
• /
• pp.261-271
• /
• 1998

The acute and subacute toxicity of New Wonbangwoohwangchungsimwon (NSCH) which was used l-muscone as substitutive material of musk were investigated in S.D. rats. In intraperitoneal acute toxicity test, rats were injected intraperitoneally with five dosages of 0, 500, 710, 1,000, 1,410 and 2,000 mg/kg. Body weights were significantly decreased at 500 and 710 mg/kg dose group in male and abnormal autopsy findings were founded in both sexes at all dose. Intraperitoneal $LD_{50}$ of NSCH was 1,088.3 mg/kg in male and 1159.3 mg/kg in female rats. In the subacute toxicity study, NSCH was administrated orally to both sexes of rats for 4 weeks as several doses(0, 320, 800, and 2,000 mg/kg). There were neither dead animals nor significant changes of body weights during the experimental period. In addition, no differences were found between control and treated groups in clinical signs, urinalysis, hematology, serum biochemical analysis, and other findings. Above data strongly suggest that no observed adverse effect level of NSCH might be over 2,000 mg/kg/day in this study.